PCT/CA00/00289 filed March 16, 2000, both assigned to the assignee hereof and the disclosures of which are incorporated herein by reference. The V38 rHia protein was chosen for further development as a vaccine, but it was found that the first 6 amino acids of this protein were deleted from a portion of the product during synthesis in *E. coli*, leading to a mixture of V38 rHia and S44 rHia. When an expression construct was developed to produce the S44 rHia, it was found that the N-terminus was stable, with only S44 rHia product being made. The rHia products appear as a doublet on SDS-PAGE when expressed alone. However, when co-expressed with H91A Hin47, the S44 rHia is produced as a single band, as described below."

Please replace the paragraph beginning at page 12, line 5, with the following rewritten paragraph:

"The *H. influenzae* Hia or Hsf proteins are demonstrated adhesins and as such are important vaccine candidates. The production of recombinant *H. influenzae* Hia proteins from *E. coli* has been described in the aforementioned US Patent No. 6,335,182. The full-length proteins were expressed at very low levels and were apparently toxic to *E. coli*. A series of truncated rHia proteins was made, which were sequentially deleted at the N-terminus. The V38 rHia protein was produced as "soft" inclusion bodies and was purified, as described in the aforementioned US Patent No. 6,335,182. When the V38 rHia protein was co-produced with mature H91A Hin47, its solubility was increased. This led to an improved recovery during protein purification, and represents a novel use of mature H91A Hin47 (Figure 8). When analysed by SDS-PAGE, the V38 rHia protein was apparently produced as two doublets, whether or not it was co-produced with mature H91A Hin47 (Fig 6)."

ax.noti

rewritten paragraph:

"Plasmid DS-1872-2-2 is a pBR328-based vector containing a 2.2 kb *EcoR* I *T7 H91A hin47* gene cassette (Figure 5). Plasmid BK-96-2-11 is a pBR328-based vector that contains a *T7 V38 hia* gene cassette, the *E. coli cer* gene, and a kanamycin resistance gene; and this plasmid has been described in the aforementioned US Patent No. 6,335,182. BK-96-2-11 was linearized by digestion with *EcoR* I, dephosphorylated, and the *EcoR* I *T7 H91A hin47* gene fragment inserted, to generate plasmid DS-2342-2-2, that co-expresses the *H91A hin47* and

Beorie

ζ,

B